In 2022, before changing its name from Sema4 to GeneDx, the company had a dispute with UnitedHealthcare, which resulted in a settlement to repay $42 million over four years. Grizzly Research's investigation suggests that the dispute was due to fraudulent code stacking, a fact that was not disclosed to investors.